Trial Profile
A Randomized, Double Blind, Two-period Cross-over Trial Investigating the Effect of Liraglutide as Add on to Intensive Insulin Treatment on the Endogenous Glucose Production in Subjects With C-peptide Positive Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Paracetamol
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- 13 Jun 2017 Results assessing effect of liraglutide on overall pancreatic islet function in C-peptide positive Type 1 Diabetes Mellitus patients, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.